Clinical trial · Interventional
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour. The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Triple-Negative Breast Carcinoma | Triple-Negative Breast Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bexarotene | Drug | Bexarotene | ALIAS |
| Capecitabine | Drug | Capecitabine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Bexarotene and Capecitabine
- interventionNames
- Drug: Bexarotene
- Drug: Capecitabine
Primary outcomes (2)
- measure
- Tumour transcriptome by RNA sequencing
- timeFrame
- From time of first biopsy before the start of treatment, to disease progression, up to 2 years
- description
- To characterize the changes in tumour transcriptome upon treatment
- measure
- Tumour protein profile by multiplex immunohistochemistry
- timeFrame
- From time of first biopsy before the start of study treatment, to disease progression, up to 2 years
- description
- To characterize the changes in tumour protein profile upon treatment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically proven metastatic TNBC * Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil * Females aged 21 years and older * ECOG performance status 0 or 1 * Life expectancy greater than three months * Patients have normal organ and marrow function * Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment Exclusion Criteria: * Previous palliative radiotherapy to potentially biopsy-able lesion * Active symptomatic central nervous system (CNS) metastases * Spinal cord compression not definitively treated with surgery and/or radiation * Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures
References
Publications (0)
Data not yet available